Literature DB >> 25974833

X-chromosome inactivation in female patients with Fabry disease.

L Echevarria1,2, K Benistan2, A Toussaint3, O Dubourg4, A A Hagege5, D Eladari6, F Jabbour2, C Beldjord3, P De Mazancourt7, D P Germain1,2,7.   

Abstract

Fabry disease (FD) is an X-linked genetic disorder caused by the deficient activity of lysosomal α-galactosidase (α-Gal). While males are usually severely affected, clinical presentation in female patients may be more variable ranging from asymptomatic to, occasionally, as severely affected as male patients. The aim of this study was to evaluate the existence of skewed X-chromosome inactivation (XCI) in females with FD, its concordance between tissues, and its contribution to the phenotype. Fifty-six females with FD were enrolled. Clinical and biological work-up included two global scores [Mainz Severity Score Index (MSSI) and DS3], cardiac magnetic resonance imaging, measured glomerular filtration rate, and measurement of α-Gal activity. XCI was analyzed in four tissues using DNA methylation studies. Skewed XCI was found in 29% of the study population. A correlation was found in XCI patterns between blood and the other analyzed tissues although some punctual variability was detected. Significant differences in residual α-Gal levels, severity scores, progression of cardiomyopathy and deterioration of kidney function, depending on the direction and degree of skewing of XCI were evidenced. XCI significantly impacts the phenotype and natural history of FD in females.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Fabry disease; X-chromosome inactivation; enzyme replacement therapy; heterozygotes; phenotype

Mesh:

Substances:

Year:  2015        PMID: 25974833     DOI: 10.1111/cge.12613

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  95 in total

1.  Cognitive Impairments and Subjective Cognitive Complaints in Fabry Disease: A Nationwide Study and Review of the Literature.

Authors:  Josefine Loeb; Ulla Feldt-Rasmussen; Christoffer Valdorff Madsen; Asmus Vogel
Journal:  JIMD Rep       Date:  2018-04-14

2.  Determinants of white matter hyperintensity burden in patients with Fabry disease.

Authors:  Natalia S Rost; Lisa Cloonan; Allison S Kanakis; Kaitlin M Fitzpatrick; Danielle R Azzariti; Virginia Clarke; Charles M Lourenco; Dominique P Germain; Juan M Politei; György A Homola; Claudia Sommer; Nurcan Üçeyler; Katherine B Sims
Journal:  Neurology       Date:  2016-04-20       Impact factor: 9.910

3.  Clinical utility gene card for: Fabry disease - update 2016.

Authors:  Andreas Gal; Michael Beck; Wolfgang Höppner; Dominique P Germain
Journal:  Eur J Hum Genet       Date:  2017-03-22       Impact factor: 4.246

Review 4.  Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.

Authors:  Malte Lenders; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2018-08-09       Impact factor: 10.121

5.  Maternal germline mosaicism in Fabry disease.

Authors:  Luigi Pianese; Antonio Fortunato; Serena Silvestri; Francesco G Solano; Alberto Burlina; Alessandro P Burlina; Michele Ragno
Journal:  Neurol Sci       Date:  2019-02-14       Impact factor: 3.307

6.  The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program.

Authors:  Sergey Moiseev; Victor Fomin; Kirill Savostyanov; Alexander Pushkov; Alexey Moiseev; Andrey Svistunov; Leyla Namazova-Baranova
Journal:  Nephron       Date:  2019-01-24       Impact factor: 2.847

7.  Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.

Authors:  Maarten Arends; Christoph Wanner; Derralynn Hughes; Atul Mehta; Daniel Oder; Oliver T Watkinson; Perry M Elliott; Gabor E Linthorst; Frits A Wijburg; Marieke Biegstraaten; Carla E Hollak
Journal:  J Am Soc Nephrol       Date:  2016-12-15       Impact factor: 10.121

8.  Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry.

Authors:  Philippe Provençal; Michel Boutin; Shaalee Dworski; Bryan Au; Jeffrey A Medin; Christiane Auray-Blais
Journal:  Bioanalysis       Date:  2016-08-15       Impact factor: 2.681

9.  Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.

Authors:  William R Wilcox; Ulla Feldt-Rasmussen; Ana Maria Martins; Alberto Ortiz; Roberta M Lemay; Ana Jovanovic; Dominique P Germain; Carmen Varas; Katherine Nicholls; Frank Weidemann; Robert J Hopkin
Journal:  JIMD Rep       Date:  2017-05-17

Review 10.  Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders.

Authors:  Monique Piraud; Magali Pettazzoni; Pamela Lavoie; Séverine Ruet; Cécile Pagan; David Cheillan; Philippe Latour; Christine Vianey-Saban; Christiane Auray-Blais; Roseline Froissart
Journal:  J Inherit Metab Dis       Date:  2018-03-19       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.